Pharmaceutical - Bristol-Myers Squibb

Filter

Current filters:

Bristol-Myers Squibb

Popular Filters

1 to 25 of 217 results

Most promising drugs of 2015 identified in new report

23-03-2015

Annual forecast finds significant increase in the number of blockbuster drug set to enter this year’s…

Bristol-Myers SquibbGlobalLCZ-696Markets & MarketingNovartisOpdivoPharmaceuticalPraluentRegeneron PharmaceuticalsSanofi

Russia’s R-Pharm in deals with AbbVie and Bristol-Myers for local production

21-03-2015

US drugmaker AbbVie has joined forces with Russia’s R-Pharm to establish the joint production of Kaletra…

AbbVieAnti-viralsBristol-Myers SquibbKaletra TabletsOncologyPharmaceuticalProductionR-PharmRussiaSprycel

NICE draft guidance recommends Eliquis for treating and preventing potentially fatal blood clots

NICE draft guidance recommends Eliquis for treating and preventing potentially fatal blood clots

06-03-2015

In draft guidance published today, the National Institute for Health and care Excellence (NICE), the…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPricingRegulationUK

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

Report: Japanese pharma market edging towards $80 Billion by 2020

Report: Japanese pharma market edging towards $80 Billion by 2020

26-02-2015

Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of…

Bristol-Myers SquibbGlobalDataJapanMarkets & MarketingPharmaceutical

Bristol-Myers Squibb to acquire Flexus; inks deal with Rigel

Bristol-Myers Squibb to acquire Flexus; inks deal with Rigel

23-02-2015

US pharma major Bristol-Myers Squibb has signed a definitive agreement to acquire all of the outstanding…

Bristol-Myers SquibbF001287FlexusLicensingMergers & AcquisitionsOncologyPharmaceuticalRigel Pharmaceuticals

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13-02-2015

German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab)…

Bristol-Myers SquibbErbituxJapanLicensingMerck & CoOncologyPharmaceutical

FDA approves Bristol-Myers Squibb's Evotaz in HIV-1

FDA approves Bristol-Myers Squibb's Evotaz in HIV-1

02-02-2015

US drug major Bristol-Myers Squibb has received approval from the US Food and Drug Administration for…

Anti-viralsBristol-Myers SquibbEvotazPharmaceuticalRegulation

Fourth quarter Bristol-Myers Squibb results disappoint

Fourth quarter Bristol-Myers Squibb results disappoint

27-01-2015

Although the fourth quarter financial results from US drug major Bristol-Myers Squibb beat analyst estimates,…

Bristol-Myers SquibbFinancialPharmaceuticalUnited StatesUSA

Moderate growth forecast for colorectal cancer drug market

22-01-2015

The value of the colorectal cancer (CRC) therapeutics market will increase moderately, from $8.3 billion…

AvastinBayerBristol-Myers SquibbErbituxGlobalMarkets & MarketingMerck KGaAOncologyPharmaceuticalRocheStivarga

Bristol-Myers to promote Caforio to CEO post; other appointments

Bristol-Myers to promote Caforio to CEO post; other appointments

21-01-2015

US pharma major Bristol-Myers Squibb yesterday announced a number of leadership changes approved by its…

BoardroomBristol-Myers SquibbManagementPharmaceuticalUSA

Bristol-Myers stops Opdivo NSCLC study early on good results

12-01-2015

US pharma major Bristol-Myers Squibb says that an open-label, randomized Phase III study evaluating Opdivo…

Bristol-Myers SquibbOncologyOpdivoPharmaceuticalResearch

Bristol-Myers Squibb enters global research accord with Calibr

06-01-2015

US pharma major Bristol-Myer Squibb has signed a worldwide research collaboration with the California…

Bristol-Myers SquibbGlobalLicensingPharmaceuticalResearchRespiratory and Pulmonary

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

23-12-2014

The US Food and Drug Administration yesterday granted accelerated approval to US pharma major Bristol-Myers…

Bristol-Myers SquibbKeytrudaMerck & CoOncologyOpdivoPharmaceuticalRegulationUSA

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' andexanet alfa reverses the effects…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearchUSA

Mixed findings from IQWiG on added benefit for Eliquis

05-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined a dossier on Eliquis…

Bristol-Myers SquibbCardio-vascularEliquisGermanyPfizerPharmaceuticalPricingRegulation

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

Clear survival benefit for B-MS’ Opdivo in advanced melanoma patients

Clear survival benefit for B-MS’ Opdivo in advanced melanoma patients

17-11-2014

US drug major Bristol-Myers Squibb has announced results from a study comparing Opdivo (nivolumab) to…

Bristol-Myers SquibbOncologyOpdivoPharmaceuticalResearchUSA

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

10-11-2014

The Scottish Medicines Consortium has approved two new treatments today, one for skin cancer and one…

Bristol-Myers SquibbDaklinzaNephrology and HepatologyOncologyPharmaceuticalRegulationUKYervoy

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Bristol-Myers Squibb signs deal with Korean company OliPass

Bristol-Myers Squibb signs deal with Korean company OliPass

28-10-2014

Privately-held Korean biopharmaceutical company OliPass has announced a worldwide strategic alliance…

Bristol-Myers SquibbOliPassPharmaceuticalResearchRest of the World

Bristol-Myers Squibb third-qtr earnings top expectations

Bristol-Myers Squibb third-qtr earnings top expectations

25-10-2014

US pharma major Bristol-Myers Squib posted a strong set of financials for the third quarter of 2014,…

Bristol-Myers SquibbFinancialPharmaceutical

1 to 25 of 217 results

Back to top